Heparinoide als eine Alternative für die parenterale Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie

A. Greinacher; S. Alban

doi:10.1055/s-0038-1656637

Hämostaseologie, Table of Contents

Hamostaseologie 1996; 16(01): 41-49
DOI: 10.1055/s-0038-1656637

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Heparinoide als eine Alternative für die parenterale Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie

A. Greinacher

¹Abteilung Transfusionsmedizin, Institut für Immunologie und Transfusions-medizin (Direktorin: Prof. Dr. C. Schütt), Ernst-Moritz-Arndt-Universität Greifswald (Leiter: Prof. Dr. A. Greinacher)

,

S. Alban

²Institut für Pharmazie, Universität Regensburg (Leiter: Prof. Dr. G. Franz)

› Author Affiliations

Abstract

Zusammenfassung

Die Heparin-induzierte Thrombozytopenie (HIT Typ II) ist eine lebensbedrohliche Komplikation der Heparintherapie. Da betroffene Patienten durch diese immunologische, unerwünschte Wirkung der Heparingabe gefährdet sind, neue throm-boembolische Gefäßverschlüsse zu entwickeln, ist bei hinreichendem klinischen Verdacht die sofortige Umstellung auf ein kompatibles Antikoagulans notwendig. Hierfür kommen, neben rekombinantem Hirudin, verschiedene Heparinoide in Betracht. Die Pathophysiologie der HIT Typ II sowie die Struktur und die anti-koagulatorischen Eigenschaften verschiedener Heparinoide werden dargestellt. Der letzte Teil des Artikels faßt den gegenwärtigen Stand der Dosierungsempfehlungen für das Heparinoid Danaparoid (Orgaran®, NV Organon, Niederlande) bei HIT-Typ-Il-Patienten zusammen.

Schlüsselwörter

Heparin - Heparin-induzierte Thrombozytopenie - Thrombozyten - Danaparoid-Natrium - Heparinoide - Heparansulfat - Chondroitinsulfat - Therapie - Antikoagulanzien

Full Text

References

LITERATUR
1 AbuRahma AF, Boland JP, Witsberger T. Diagnostic and therapeutic strategies of white clot syndrome. Am J Surg 1991; 162: 175-9
2 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6
3 Anderson GP. Insights into heparin-induced thrombocytopenia. Br J Haematol 1992; 80: 504-8
4 Banga JD, de Valk HW, Wester JWJ. et al. A dose-finding study of subcutaneous hepari-noid Orgaran (Org 10172) twice daily compared to continuous intravenous un-fractionated heparin in the treatment of venous thromboembolism. Thromb Haemost (Abstracts of XlVth ISTH congress NY) 1993; 69 (Abstr. 20) 545
5 Barbanti M, Calani F, Milani MR. et al. Therapeutic effect of low molecular weight dermatan sulfate (Desmin 370) in rat venous thrombosis - evidence for an anticoagulant-independent mechanism. Thromb Haemost 1993; 69: 147-51
6 Barbanti M, Guizzardi S, Calanni F. et al. Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res 1992; 22: 179-84
7 Bergqvist D, Lindblad B, Mätzsch T. Glyc-osaminoglycans in prophylaxis against venous thromboembolism. In:. Lane DA, Björk I, Lindahl U. (eds) Heparin and Related Polysaccharides. New York: Plenum Press; 1992: 259-74
8 van Besien K, Hoffman R, Golichowski A. Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. Thromb Res 1991; 62: 23-9
9 Bianchini P, Osima B, Parma B. et al. Lack of correlation between 'in vitro' and 'in vivo' antithrombotic activity of heparin fractions and related compounds. Heparan sulfate as an antithrombotic agent 'in vivo'. Thromb Res 1995; 39: 21-8
10 Bleasel JF, Rasko JEJ, Richard KA, Richard G. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia thrombosis syndrome. Med J Aust 1992; 157: 192-3
11 van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. An-gew Chem Int Ed Engl 1993; 32: 1671-90
12 Buchanan MR, Liao P, Smith LJ, Ofosu FA. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II. Thromb Res 1994; 74: 463-75
13 Callas DD, Hoppensteadt DA, Jeske W. et al. Comparative pharmacological profile of a glycosaminoglycan mixture, Sulodexide®, and a chemically modified heparin derivative, Suleparoide®. Semin Thromb Hemost 1993; 19 (Suppl. 01) 49-57
14 Cannell PK, Herrmann RP, Marshall L. Heparinoid during cardiopulmonary bypass. Aust NZ J Med 1991; 21 (Suppl. 01) 141
15 Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 1989; 58: 53-7
16 Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the hepa-rin-dependent antibody with platelets. Br J Haematol 1989; 73: 235-40
17 Chong BH, Ismail F, Cade J. et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592-6
18 Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992; 22: 85-91
19 Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-asso-ciated thrombocytopenia. N Engl J Med 1987; 316: 581-9
20 Condorelli M, Chiariello M, Dagianti A. et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovasular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol 1994; 23: 27-34
21 Danhof M, de Boer A, Magnani HN, Stieke-ma JC. Pharmacokinetic considerations of Orgaran (Orgl0172) therapy. Haemostasis 1992; 22: 73-84
22 Dawes J. Measurement of the affinities of heparins, naturally occuring GAGs, and other sulfated polymers for antithrombin III and thrombin. Anal Biochem 1988; 174: 177-86
23 Doherty DC, Ortel TL, De Bruijn N. et al. »Heparin-free« cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990; 73: 562-5
24 Dol F, Petitou M, Lormeau JC. et al. Pharmacologic properties of a low molecular weight dermatan sulfate (4kDa): comparison with unfractionated dermatan sulfate (25kDa). J Lab Clin Med 1990; 115: 43-51
25 Fareed J, Hoppensteadt D, Jeske W, Walenga JM. An overview of non-heparin glycos-aminoglycans as antithrombotic agents. In: . Poller L. (ed) Recent Advances in Blood Coagulation. London: Churchill Livingstone; 1993: 169-87
26 Fischer AM, Dautzenberg MD, Aurousseau MH. et al. Comparison between the effect of pentosan polysulphate, heparin and antithrombin III injections in antithrombin III. Thromb Res 1985; 37: 295-307
27 Goad HE, Home MK , Gralnick HR. Pentosan-induced thrombocytopenia: support for an immune complex mechanism. Br J Haematol 1994; 88: 803-8
28 Gordon DL, Libhardt R, Adams HP. Low molecular weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clin Neuropharmacol 1990; 13: 522-43
29 Greinacher A. The nonimmunologic type I and the immunologic type II of heparin associated thrombocytopenia are closely linked in their pathogenesis. Semin Thromb He-most 1995; 21: 106-16
30 Greinacher A, Amiral J, Dummel Vissac A. et al. Laboratory diagnosis of heparin-asso-ciated thrombocytopenia and comparison of platelet aggregation test, heparin-induced activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381-5
31 Greinacher A, Alban S, Dummel V. et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunologic type of heparin associated thrombocytopenia. Thromb Haemost 1995; 74: 886-92
32 Greinacher A, Drost W, Michels I. et al. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW-heparins. Ann Hematol 1992; 64: 40-2
33 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992; 67: 545-9
34 Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-6
35 Greinacher A, Michels I, Liebenhoff U. et al. Heparin-associated thrombocytopenia: immune complexes are attached to platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 1993; 45 (03) 252-7
36 Greinacher A, Pötzsch B, Amiral J. et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-51
37 Harenberg J, Zimmerman R, Schwarz F, Kubler W. Treatment of heparin-induced thrombocytopenia with thrombosis by new heparinoid. Lancet 1983; i: 986-7
38 Herbert JM, Hérault JP, Barzu T. et al. Biochemical and pharmacological properties of SANORG 32701; a potent analogue of the 'natural pentasaccharide'. Thromb Haemost 1995; 73: 1321
39 Henny CP, ten Cate H, ten Cate JW. et al. Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid. Thromb Haemost 1986; 55: 301
40 Henny CP, ten Cate H, ten Cate JW. et al. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983; i: 890-3
41 Hoppensteadt D, Walenga J, Fareed J. Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin. Semin Thromb Hemost 1991; 17 (Suppl. 01) 60-4
42 Horellou MH, Conard J, Lecrubier C. et al. Persistent heparin induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemost 1984; 51: 134
43 John G, Shehabi Y, Mudaliar Y. Use of low molecular weight preparation of heparin-Org 10172 (Lomoparan) in the critically ill. Anaesth Intensive Care 1991; 588-91
44 Kelton JG, Sheridan D, Santos A. et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-30
45 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535-40
46 Kiers L, Grigg LE, Cade JF. et al. Use of Org 10172 in the treatment of heparin-induced thrombocytopenia and thrombosis. Aust NZ J Med 1986; 16: 719
47 Klauser RJ. Interaction of the sulfated lacto-bionic acid amide LW 10082 with thrombin and its endogenous inhibitors. Thromb Res 1991; 62: 557-65
48 Klauser RJ, Meinetsberger E, Raake W. Biochemical studies on lactobionic acid amides. Semin Thromb Hemost 1991; 17 (Suppl. 01) 118-25
49 Leroy J, Leclerc MH, Delahousse B. et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost 1985; 11: 326-9
50 Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61 and 1072;
51 Mascellani G, Liverani L, Bianchini P. et al. Structure and contribution of the heparin co-factor Il-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulfate. Biochem J 1993; 296: 639-48
52 Marcum JA, Rosenberg RD. Regulation of the blood coagulation mechanism by antico-agulantly active heparan sulfate proteoglycans. Biol Carbohydr 1991; 3: 47-73
53 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulfate and heparin as antithrombotic agents. Thromb Haemost 1987; 58: 839-42
54 Messmore HL, Griffin B, Koza M. et al. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparin. Semin Thromb Hemost 1991; 17: 57-64
55 Meuleman DG. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992; 22: 58-65
56 Meuleman DG. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models. Semin Thromb Hemost 1989; 15: 370-2
57 Nader HB, Toma L, Pinhal MS. et al. Effect of heparin and dextran sulfate on the synthesis and structure of heparan sulfate from cultured endothelial cells. Semin Thromb Hemost 1991; 17: 47-56
58 Nawa K, Sakano K, Fujiwara H. et al. Presence and function of chondroitin-4-sulfate on recombinant human soluble thrombomodulin. Biochem Biophys Res Commun 1990; 171: 729-37
59 Nieuwenhuis HK, Sixma JJ. Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer 1986; 58: 761-4
60 Ofosu FA. Anticoagulant mechanisms of Orgaran (Org 10172) and its fractions affinity to antithrombin III (Org 10849). Haemostasis 1992; 22: 66-72
61 Ofosu FA, Choay J, Anvari N. et al. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma. Eur J Biochem 1990; 193: 485-93
62 Ortel TL, Gockerman JP, Cliff RM. et al. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin-induced thrombocytopenia and thrombosis. Thromb Haemost 1992; 292-6
63 Raake W, Klauser RJ, Meinetsberger E. et al. Pharmacological profile of the antithrombotic and bleeding actions of sulfated lactobionic acid amides. Semin Thromb Hemost 1991; 17 (Suppl. 01) 129-35
64 Rowlings PA, Mansberg R., Rozenberg MC. et al. The use of a low molecular weight heparin (Org 10172) for extracorporeal procedures in patients with heparin-induced thrombocytopenia and thrombosis. Aust NZ J Med 1991; 21: 52-4
65 Roth B, Johnen M, Herkenrath P, Schütz F. Anwendung eines neuen Heparinoids zur Antikoagulation bei der Hämodialyse eines Kindes mit intrakranieller Blutung. Nieren und Hochdruckkrankheiten 1985; 14: 62-4
66 Saivin S, Dol F, Caranobe C. et al. Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit. Thromb Res 1992; 66: 527-35
67 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30
68 Sina P, Jacquinet JC, Petitou M. et al. Total synthesis of a pentasaccharide fragment having high affinity for antithrombin III. Carbohydr Res 1984; 132: C5-C9
69 Tardy PB, Tardy B, Grelac F. et al. Pentosan polysulfate-induced thrombocytopenia and thrombosis. Am J Hematol 1994; 88 (04) 803-8
70 Ten Cate H, Henny CP, Büller HR. et al. Use of a heparinoid in patients with haemorrhagic stroke and thromboembolic disease. Ann Neurol 1984; 15: 268-70
71 Visentin GP, Ford SE, Scott JP. et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexe with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8
72 Volpi N, Cusmano M, Venturelli T. Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim Biophys Acta 1995; 1243: 49-58
73 Wagenvoord R, Hendrix H, Soria C. et al. Localization of the inhibitory site(s) of pentosan polysulphate in blood coagulation. Thromb Haemost 1988; 60: 220-5
74 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991; 10: 1-34
75 Warkentin TE, Levine MN, Hirsh J, Hemker HC. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-4